Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships
Source: SeekingAlpha
2025-10-29 19:57:00 ET
More on Bio-Rad Laboratories, Inc.
- Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
- Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
- Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
- Bio-Rad Laboratories, Inc. Non-GAAP EPS of $2.26 beats by $0.33, revenue of $653M beats by $1.7M
- Bio-Rad Laboratories, Inc. Q3 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships
Bio-Rad Laboratories Inc. Class A
NASDAQ: BIO
BIO Trading
10.59% G/L:
$275.17 Last:
337,937 Volume:
$274.72 Open:
BIO Latest News
BIO Stock Data
$8,088,674,023
21,121,296
0.01%
179
N/A
Biotechnology & Life Sciences
Healthcare
US
Hercules
